News

A recent report shared the market's expansion is mainly driven by the growing prevalence of chronic diseases, which has increased the demand for remote health monitoring and efficient healthcare solutions.

The answer is no. Research findings reported in JAMA Network Open show no association between hepatitis B status and poor birth outcomes among those who get pregnant with freeze-thaw embryo transfer whereas among natural births, hepatitis B infection in mothers is linked to miscarriage and preterm birth.

Two studies show that high heart failure rates in the Black population are a legacy of discriminatory mortgage policies.

Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.

In a study conducted from January to September 2022, 268 United States counties within 22 states participated in the U.S. Centers for Disease Control and Prevention’s National Wastewater Surveillance System (NWSS).

The newly formed Peterson Health Technology Institute was launched with $50 million to analyze clinical benefits and economic impact of new health technologies.

The manufacturer has reported seven causes of retinal vasculitis associated with Syfovre. Results of an open-label, extension study presented at the American Society of Retina Specialists meeting today show favorable results among those who crossed over from sham to active treatment.

The approval of an ophthalmic bevacizumab biosimilar might mean the end of low-cost, repackaged Avastin as an anti-VEGF treatment for retinal diseases, with the unintended consequence of adding $457 million to Medicare B spending.

In an interview with MHE, Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, talked about the latest geographic atrophy treatments, pegcetacoplan and avacincaptad pegol, from a coverage and healthcare resource utilization standpoint, as both will potentially be available for the chronic disease that previously had no treatments.

Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, chatted with MHE about the latest geographic atrophy treatments and shared key takeaways found from clinical trials examining them. Hahn presented on macular degeneration today at the American Society of Retina Specialists annual meeting in Seattle.

About 20% of patients in the trial of a high-dose, longer-interval regimen of Eylea (aflibercept )switched to shorter intervals, according to data presented today at the American Society of Retinal Specialists annual scientific meeting, which is being held in Seattle. Researchers didn't find any clues as to why in their baseline characteristics.

Research shows a $12,575 savings over two years and no difference in outcome, which result in an incremental cost-effectiveness ratio (ICER) of $873,000.

A post-hoc analysis didn’t reveal any differences in outcomes by race, macular thickness or baseline visual acuity.

In an interview with Managed Healthcare Executive prior to the meeting, Keyvan Koushan, M.D., a retina specialist at the Toronto Retina Institute and a lecturer in the Department of Ophthalmology and Vision Sciences at the University of Toronto, briefly described the design of the PULSAR trial and the positive results that have been reported so far.

The Value in Health Care Act of 2023, a bipartisan legislation that would make several important reforms to ensure alternative payment models (APMs) continue to produce high quality care for the Medicare program and its beneficiaries, was introduced in a letter signed by seventeen of the nation’s leading stakeholders in healthcare.

FDA approvals this week include the second nonprescription naloxone nasal spray for opioid overdose, the first drug for a skin infection from pox virus and a drug to treat an eye infection caused by mites. In addition, the FDA has accepted a supplemental application for Ofev in children with rare lung disease.

Pros and cons of Syfovre (pegcetacoplan), the newly approved drug for geographic atrophy will be discussed at the American Society of Retinal Specialists annual scientific meeting in Seattle this weekend, predicts leading member of the society. Biosimilars are also on the agenda.

Charles Wykoff, M.D., Ph.D., director of clinical research at Retina Consultants of Texas, noted new treatments for geographic atrophy are predicted to be a hot topic at the American Society of Retina Specialists annual scientific meeting that starts today in Seattle.

The supply of fentanyl, epinephrine injection, and heparin, however, have been impacted by the July 19 tornado at Pfizer's North Carolina facility.

Results from a recent study reveal insured Americans believe health insurance is not living up to providing affordable and accessible healthcare.

UnitedHealthcare is awarding $11.1 million in grants to 66 nonprofit organizations through its Empowering Health program across 12 states to help uninsured individuals and underserved communities.

Three hot topics to keep an eye on for the remainder of this year and into 2024. This is the second part of a two-part series.

The study will enroll an estimated 1,000 patients, of whom approximately 200 will have vitiligo. The remaining participants will be at-risk family members, some 40 to 60 of whom are expected to develop vitiligo during the 5-year study.

Three hot topics to keep an eye on for the remainder of this year and into 2024. This is the first part of a two-part series.

Eric Hunter, MBA, has been president and CEO of CareOregon, a 500,000-member Medicaid managed care organization, since 2016. This interview was conducted in May for Managed Healthcare Executive’s monthly “What’s On Your Mind” podcast.

The FDA has cleared several new products this week, including the first monoclonal antibody for RSV in infants, a novel therapy for newly diagnosed patients with AML and a postexposure anthrax vaccine. Additionally, an FDA decision on donanemab for Alzheimer’s is expected by the end of this year.